申请人:COLD SPRING HARBOR LABORATORY
公开号:WO2022159436A1
公开(公告)日:2022-07-28
Provided is a compound, including a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein W is a direct bond or an optionally substituted C, and if W is a direct bond, then X1, X2, X3, and X4are each independently H, OH, or an electrophile, and optionally one pair selected from X1and X2, X2and X3, and X3and X4forms a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a =C, an =S, or an electrophile, and Y1, Y2, Y3, Y4and Y5are each independently selected from H, CH3, OH, O-CH3, and NO2, and an electrophile, and optionally Y2and Y3form a five-membered ring including one or more heteroatom, wherein the one or more heteroatom is selected from O, N, and S, and the five-membered ring is optionally substituted with a =C, =S, or an electrophile.
提供的是一种化合物,包括式I的化合物或其药学上可接受的盐,其中W是直接键或可选取代的C,如果W是直接键,则X1、X2、X3和X4各自独立地为H、OH或亲电子,且可选取一对从X1和X2、X2和X3、X3和X4中选择的原子形成包括一个或多个杂原子的五元环,其中一个或多个杂原子选自O、N和S,且该五元环可选取代为=C、=S或亲电子,Y1、Y2、Y3、Y4和Y5各自独立地选择自H、CH3、OH、O-CH3和NO2以及亲电子,如果需要,则Y2和Y3可形成包括一个或多个杂原子的五元环,其中一个或多个杂原子选自O、N和S,且该五元环可选取代为=C、=S或亲电子。